ISSN: 1885-5857 Impact factor 2023 7.2
Vol. 68. Num. 9.
Pages 816-817 (September 2015)

Scientific letter
Lipophylic Statins in Heart Failure

Estatinas lipófilas en la insuficiencia cardiaca

Rafael RamírezabLidia TikhomirovaaJavier MárquezaMeritxell MasaMontserrat DuránaOlga Araújoa
Rev Esp Cardiol. 2016;69:23210.1016/j.rec.2015.10.004
Julio Núñez, Gema Miñana, Luciano Consuegra-Sánchez

Options

To the Editor,

Current clinical practice guidelines do not recommend the use of statins in heart failure (HF).1 This recommendation is supported by 2 trials that studied hydrophilic statins.2,3 We conducted a retrospective study of patients admitted with HF between December 2007 and June 2011 to Hospital de Santa Tecla, Spain. The primary objective was to analyze the usefulness of lipophilic statins in these patients and the secondary objective was to compare real use with the theoretical indication for statins. Exclusion criteria were patients younger than 18 years or older than 85 years, those with neoplastic, infectious, or end-stage disease, and those receiving hydrophilic statins. We reviewed 680 patients, and considered only the first admission in patients who were re-admitted during the study. We compared patients receiving lipophilic statins with those not receiving any statins, and we calculated the percentage of patients who fulfilled the theoretical indications for receiving statins in accordance with the European Society of Cardiology Guidelines for the management of dyslipidemias.4 Quantitative variables are expressed as mean ± standard deviation, and data were compared with the Student t test or ANOVA. We used the chi-square test to compare qualitative variables, the Mann-Whitney test for nonparametric data, and logistic regression for the multivariable analysis. The SPSS package version 20.0 was used for the statistical analysis. Statistical significance was defined as P<.05.

A total of 270 patients were enrolled (Table 1). Compared with the nonstatin group, the statin group had lower levels of low-density lipoprotein cholesterol (LDL-C) (80±25mg/dL vs 98±35mg/dL; P=.01), hemoglobin (11.6±1.9g/L vs 12.2±2.2g/L; P=.04), and glomerular filtration rate (55.2±23mL/min/m2 vs 61.5±26mL/min/m2; P=.04). There was a higher prevalence of treatment with aspirin, clopidogrel, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the statin group than in the nonstatin group (45.4% vs 26.5%; P=.01; 33.6% vs 13.5%; P<.001; and 76.1% vs 53%; P=.01, respectively). The statin group also had a higher prevalence of hypertension, diabetes mellitus and dyslipidemia, and HF of ischemic etiology. There were no differences in cardiovascular or all-cause mortality or re-admission (Table 2). A multivariable regression was performed, adjusting for age, sex, hypertension, diabetes mellitus, dyslipidemia, HF of ischemic etiology, glomerular filtration rate (< 60mL/min/m2), anemia (hemoglobin<12 g/L) and LDL-C (< 80mg/dL). We found that lipophilic statins were not associated with cardiovascular mortality (odds ratio [OR]=1.12; 95% confidence interval [95%CI], 0.22-5.64; P=.88) or all-cause mortality (OR=4.94; 95%CI, 0.90-27.11; P=.06), or with cardiovascular re-admission (OR=0.91; 95%CI, 0.63-1.34; P=.66) or all-cause re-admission (OR=1.06; 95%CI, 0.82-1.38; P=.61). In theory, at least 84.9% of the study patients should have been receiving statin therapy, but in practice, this figure was 40.9%.

Table 1.

Characteristics of the Study Patients

Patients, n  270 
Age, years  74±
Men  55.3 
DLP  40.9 
DM  47.6 
HT  73.3 
Smoker  17.0 
Atherosclerotic history
Cerebrovascular disease (ischemic)  15.7 
Ischemic heart disease  46.7 
Peripheral arterial disease  15.0 
Any cardiovascular disease  58.8 
Etiology
Ischemic  46.0 
Arrhythmogenic  49.6 
Valvular  27.7 
Hypertensive  40.1 
Treatment
Statins  40.9 
Clopidogrel or ASA  44.3 
ARB or ACE inhibitors  61.5 
Aldosterone antagonists  13.5 
Beta-blockers  31.8 
Diuretics  63.5 
EF, %  49.6 ± 14.3 

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; DLP, dyslipidemia; DM, diabetes mellitus; EF, ejection fraction; HT, hypertension; NYHA, New York Heart Association functional class.

Data are expressed as a percentage or mean±standard deviation, unless otherwise indicated.

Table 2.

Clinical Data and Lipid Profile of Patients Receiving Lipophilic Statins and Those not Receiving Statins

  Lipophilic statins  No statins  P 
Patients, n  106  164   
Age, years  75.2±7.3  74.1±9.1  .30 
Men  58  52.8  .23 
DLP  66  23  <.001 
DM  57  40  .05 
HT  88  64  <.001 
Smoker  17  17  .37 
EF, %  48.4±15.5  50.4±13.3  .30 
NYHA
II  34  31  .79 
III  31  31  .66 
IV  28  29  .67 
Etiology
Ischemic  58  34  <.00 
Arrhythmogenic  43  53  .06 
Valvular  32  24  .11 
Hypertensive  45  35  .08 
Lipid profile, mg/dL
Total cholesterol  149±35.5  158±42.0  .07 
LDL-C  80±25  98±35  .01 
HDL-C  42±41±12  .68 
Triglycerides  130±53  118±66  .13 

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; DLP, dyslipidemia; DM, diabetes mellitus; EF, ejection fraction; HT, hypertension; NYHA, New York Heart Association functional class;.

Data are expressed as a percentage or mean±standard deviation, unless otherwise indicated.

This study has similar characteristics to those reported in recent studies in our setting.5 The higher prevalence of hypertension, diabetes mellitus, dyslipidemia, and HF of ischemic etiology in patients receiving lipophilic statins is probably explained by worse underlying atherosclerosis. In fact, 58.8% of all patients had already experienced an ischemic event before admission. Both the lower glomerular filtration rate and the higher prevalence of antiplatelet agents and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers can be similarly explained. Patients receiving lipophilic statins had lower LDL-C levels, but these levels did not result in improved clinical outcome. While statins do indeed prevent the onset of ischemic events, there is also a known association between very low cholesterol levels and lower survival in HF.1 Furthermore, anemia is associated with more re-admissions and lower survival in elderly, hospitalized patients with HF,1 an association corroborated by our study. The multivariable regression analysis showed no association between lipophilic statins and lower cardiovascular or all-cause re-admissions or mortality. The equivalent mean atorvastatin dose in our study (54.6 mg) may not have been high enough to produce evidence of these benefits, because a post hoc analysis of high-dose lipophilic statins found that they do appear to be useful in HF.6 Evidence of lower re-admission rates for HF reported with hydrophilic statins2 means that we should reconsider whether statin solubility plays a role in this context. Finally, only 40.9% of patients in our study were receiving statin therapy, which is much lower than the 85.9% calculated according to current guidelines for the management of dyslipidemias.4

In light of these results, it appears reasonable to maintain statin therapy at least in patients with HF of atherosclerotic origin.

References
[1]
J.V. John, J.J.V. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
Eur Heart J., (2012), 33 pp. 1787-1847
[2]
J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, J.H. Cornel, et al.
Rosuvastatin in older patients with systolic heart failure.
N Engl J Med., (2007), 357 pp. 2248-2261
[3]
L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, R. Latini, et al.
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Lancet., (2008), 372 pp. 1231-1239
[4]
Z. Reiner, A.L. Catapano, G. de Backer, I. Graham, M.R. Taskinen, O. Wiklund, et al.
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J., (2011), 32 pp. 1769-1818
[5]
P. Gastelurrutia, J. Lupón, M. de Antonio, A. Urrutia, C. Díez, R. Coll, et al.
Statins in heart failure: the paradox between large randomized clinical trials and real life.
Mayo Clin Proc., (2012), 87 pp. 555-560
[6]
K.K. Khush, D.D. Waters, V. Bittner, P.C. Deedwania, J.C. Kastelein, S.J. Lewis, et al.
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
Circulation., (2007), 115 pp. 576-583
Copyright © 2015. Sociedad Española de Cardiología
Are you a healthcare professional authorized to prescribe or dispense medications?